{"id":"W4416391865","doi":"10.1016/j.annonc.2025.09.095","title":"LBA80 Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"David Geffen School of Medicine, University of California, Los Angeles; Ono Pharmaceutical; Yonsei University College of Medicine; Seoul National University; European Society for Medical Oncology; College of Medicine, Seoul National University; Genentech; Seoul National University Hospital; KU Leuven; Weill Cornell Medical College; National Institute for Health and Care Research; Pfizer; Yonsei University; Memorial Sloan-Kettering Cancer Center; Cancer Research Institute; AstraZeneca; American Society of Clinical Oncology; Université de Montréal; University of Victoria; Daiichi Sankyo Europe; Gilead Sciences; Hospital de Câncer de Barretos; Amgen; Ipsen; BeiGene","keywords":"Nivolumab; Regorafenib; Refractory (planetary science); Chemotherapy; Gastroesophageal Junction; Phases of clinical research; Ramucirumab","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001609998,0.001303724,0.002056189,0.0003244758,0.0003436625,0.00115311,0.0008569607,0.001185721,0.004092265],"category_scores_gemma":[0.001467933,0.000488281,0.002421795,0.0003694192,0.0007131296,0.0009376259,0.0003877915,0.003168954,0.0008948935],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001021555,"about_ca_system_score_gemma":0.001224384,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00238518,"about_ca_topic_score_gemma":0.006119915,"domain_scores_codex":[0.9995073,0.0002690967,0.00002014132,0.00007458939,0.00003345526,0.00009541221],"domain_scores_gemma":[0.9993759,0.0001511849,0.0001353125,0.00006029378,0.00002677082,0.0002504875],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9482253,0.007669461,0.003664128,0.0003965053,0.002218307,0.00003632467,0.00008185273,0.001170708,0.001883087,0.0001597856,0.002236476,0.03225791],"study_design_scores_gemma":[0.8556327,0.1215582,0.01484588,0.0001029245,0.002886252,0.00006192666,0.0001145601,0.001790435,0.0005474891,0.0004423209,0.001977127,0.00004015021],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921056,0.003259953,0.0001912246,0.0005955608,0.0003015744,0.0004577341,0.0006506091,0.00005562756,0.002382173],"genre_scores_gemma":[0.991684,0.00171563,0.0006406025,0.001134206,0.0004039995,0.0006361195,0.001257497,0.00002453857,0.002503527],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004092265,"threshold_uncertainty_score":0.01369005,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06575530322274843,"score_gpt":0.4238620774123215,"score_spread":0.358106774189573,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}